Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 inhibitor plus compound betamethasone as first-line therapy for acute gouty arthritis
ChiCTR2600121829Phase 4Not yet recruiting
- Sponsor
- Henan Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of betamethasone in acute gout flare, sponsored by Henan Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: 12-week gout flare recurrence rate and Time to >50% reduction in pain score. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
betamethasone
03
Conditions
acute gout flare
Beyond the preview
Go deeper on ChiCTR2600121829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121829.